Alcon acquires LENSAR for $14.00/share cash plus CVR up to $2.75, total ~$430M

LENSAR, Inc.

Per-share consideration: $14.00 cash plus contingent value right (CVR) of up to $2.75 if 614,000 cumulative procedures achieved by Dec 31, 2027.
Total potential consideration of ~$430M; represents 24% premium to 30-day VWAP and 47% to 90-day VWAP.
North Run affiliates, representing ~45.8% of voting power, entered voting agreement to support the merger.
Transaction expected to close mid-to-late 2025, subject to regulatory approvals and LENSAR stockholder approval.
LENSAR's ALLY Robotic Cataract Laser System and Streamline software strengthen Alcon's cataract equipment portfolio.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.